Trial Profile
Impact of Patient Support From Medical Staff on the Adherence to Therapy With PegIntron Plus Rebetol
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 21 Jul 2008 New trial record.